# Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction

> **NCT05477498** · PHASE4 · WITHDRAWN · sponsor: **Cantonal Hosptal, Baselland**

## Conditions studied

- Heart Failure With Normal Ejection Fraction
- Iron-deficiency

## Interventions

- **DRUG:** Ferric carboxymaltose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05477498
- **Lead sponsor:** Cantonal Hosptal, Baselland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Principal Investigator left institution
- **Last updated:** 2022-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477498, "Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05477498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*